Massive Review Confirms Cannabinoids Reduce Pain in Animal Studies

A meta-analysis of 374 animal studies found that cannabinoid receptor agonists, including THC, consistently reduced pain behaviors across inflammatory and neuropathic pain models, though study quality was often unclear.

Soliman, Nadia et al.·Pain·2021·Strong EvidenceMeta-Analysis
RTHC-03536Meta AnalysisStrong Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Meta-Analysis
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

Across 374 studies testing 171 interventions, selective CB1, CB2, and nonselective cannabinoid agonists (including THC) plus PPAR-alpha agonists significantly reduced pain in both inflammatory and neuropathic models, while FAAH inhibitors, MAGL inhibitors, and CBD were effective in neuropathic but showed mixed results in inflammatory pain.

Key Numbers

374 studies; 171 interventions; 86% used male animals only; CB1, CB2, and nonselective agonists effective across pain models; CBD effective for neuropathic but mixed for inflammatory pain; FAAH and MAGL inhibitors effective for neuropathic pain; low reporting of bias mitigation measures.

How They Did This

PRISMA-compliant systematic review and meta-analysis of 374 rodent studies (searched April 2019), using crowd science and machine learning for study identification, with standardized mean difference effect sizes and random-effects modeling.

Why This Research Matters

This is the largest systematic evaluation of cannabinoid pain relief in animal models, providing a comprehensive evidence base to guide which cannabinoid approaches are most promising for translation to human clinical trials.

The Bigger Picture

The consistent analgesic effects across a wide range of cannabinoid compounds and pain models support the biological plausibility of cannabinoid-based pain treatment, but the heavy male bias in animal research raises questions about generalizability.

What This Study Doesn't Tell Us

Animal models may not predict human efficacy; 86% of studies used only male animals; low reporting of bias mitigation criteria makes risk of bias unclear; measures limited to evoked limb withdrawal.

Questions This Raises

  • ?Would the same compounds show efficacy in female animals?
  • ?Which specific cannabinoid types are most promising for clinical translation to human pain treatment?

Trust & Context

Key Stat:
374 studies confirmed cannabinoid-induced analgesia across inflammatory and neuropathic pain models
Evidence Grade:
Very large meta-analysis with rigorous methodology, though based on animal models with unclear risk of bias and heavy male-animal bias.
Study Age:
Systematic search conducted April 2019.
Original Title:
Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain.
Published In:
Pain, 162(Suppl 1), S26-S44 (2021)
Database ID:
RTHC-03536

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer
This study
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Combines results from multiple studies to find an overall pattern.

What do these levels mean? →

Frequently Asked Questions

Do cannabinoids actually reduce pain?

In animal models, yes. This meta-analysis of 374 studies found consistent pain reduction with cannabinoid receptor agonists including THC. However, translating animal results to humans is not always straightforward.

Does CBD work for pain?

In this review, CBD significantly reduced pain behaviors in neuropathic (nerve-related) pain models but showed mixed results for inflammatory pain, suggesting it may be more effective for certain pain types.

Read More on RethinkTHC

Cite This Study

RTHC-03536·https://rethinkthc.com/research/RTHC-03536

APA

Soliman, Nadia; Haroutounian, Simon; Hohmann, Andrea G; Krane, Elliot; Liao, Jing; Macleod, Malcolm; Segelcke, Daniel; Sena, Christopher; Thomas, James; Vollert, Jan; Wever, Kimberley; Alaverdyan, Harutyun; Barakat, Ahmed; Barthlow, Tyler; Bozer, Amber L Harris; Davidson, Alexander; Diaz-delCastillo, Marta; Dolgorukova, Antonina; Ferdousi, Mehnaz I; Healy, Catherine; Hong, Simon; Hopkins, Mary; James, Arul; Leake, Hayley B; Malewicz, Nathalie M; Mansfield, Michael; Mardon, Amelia K; Mattimoe, Darragh; McLoone, Daniel P; Noes-Holt, Gith; Pogatzki-Zahn, Esther M; Power, Emer; Pradier, Bruno; Romanos-Sirakis, Eleny; Segelcke, Astra; Vinagre, Rafael; Yanes, Julio A; Zhang, Jingwen; Zhang, Xue Ying; Finn, David P; Rice, Andrew S C. (2021). Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain.. Pain, 162(Suppl 1), S26-S44. https://doi.org/10.1097/j.pain.0000000000002269

MLA

Soliman, Nadia, et al. "Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain.." Pain, 2021. https://doi.org/10.1097/j.pain.0000000000002269

RethinkTHC

RethinkTHC Research Database. "Systematic review and meta-analysis of cannabinoids, cannabi..." RTHC-03536. Retrieved from https://rethinkthc.com/research/soliman-2021-systematic-review-and-metaanalysis

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.